Advertisement

Topics

Cue Biopharma Enters Strategic Research Collaboration and License Agreement with Merck

10:32 EST 17 Nov 2017 | Speciality Pharma Journal

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cue Biopharma™, Inc., an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer and autoimmune diseases, today announced a strategic research collaboration and license agreement with Merck, known as MSD outside of the United States and Canada. Under the terms of the …

Original Article: Cue Biopharma Enters Strategic Research Collaboration and License Agreement with Merck

NEXT ARTICLE

More From BioPortfolio on "Cue Biopharma Enters Strategic Research Collaboration and License Agreement with Merck"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...